Enliven Therapeutics, Inc. (ELVN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US29337E1029
Enliven Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -119.66 m USD |
| EBIT | -103.69 m USD |
| Net income | -103.69 m USD |
| Diluted EPS – continuing operations | -1.83 USD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
More stocks
- Greggs PLC (GRG.L)
- MARZETTI CO (MZTI)
- Digital China Group Co Ltd (000034.SZ)
- Seadrill Ltd (SDRL)
- Minmetals Capital Co Ltd (600390.SS)
- InnoDisk (5289.TWO)
- Alarm.com Holdings, Inc. (ALRM)
- Jones Tech PLC Class A (300684.SZ)
- Jiangsu Boqian New Materials Stock Co Ltd (605376.SS)
- Tasly Pharmaceutical Group Co Ltd (600535.SS)
- KeyMed Biosciences Inc (2162.HK)
- Knife River Corp (KNF)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.